| Srl | Item |
| 1 |
ID:
145954
|
|
|
|
|
| Summary/Abstract |
China's Eurasian frontiers have emerged as a major factor in Beijing's foreign policy through President Xi Jinping's “One Belt, One Road” strategy. The article argues that this strategy has been given impetus by the shifting geopolitical landscape in Central Asia resulting from the U.S. withdrawal from Afghanistan, Russia's relative decline, and Beijing's quest for stability in its restive province of Xinjiang.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2 |
ID:
128315
|
|
|
|
|
| Publication |
2013.
|
| Summary/Abstract |
As a member of Asia, China's development is rooted in Asia, and Asia has always been a priority on China's diplomatic agenda. China's growth has benefited from a peaceful neighboring area and, in turn, promoted stability and prosperity in Asia. At the same time, China and its neighbors are faced with both historic opportunities and challenges in development. Since the new government in China took office in 2013, China and other Asian countries have had frequent high-level exchanges and stronger cooperation in the field of economy and trade. China actively upholds peace and stability in the region and is working with other Asian countries to build a bright future for an Asian community of shared destiny.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3 |
ID:
156726
|
|
|
|
|
| Summary/Abstract |
This essay analyses one of the most common yet stagnated concepts of European politics—the common security and defense prospects of Europe. The analysis shows that although a common security and defense cooperation scheme has been a mainstay of European political discourse since the end of World War II, discussion never resulted in a concrete or realistic plan. The reasons for this emphatic failure can be found in the political complexities of the European structure and in the difficulties of implementing such a challenging plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4 |
ID:
119619
|
|
|
| 5 |
ID:
144006
|
|
|
|
|
| Summary/Abstract |
India is a country of enormous prospects in the field of economics, commerce and trade and many more things. The irony is that India itself does not recognise it. It is like a sleeping lion. The time has come for the lion to awaken and very rightly so the Prime Minister’s flagship programme of ‘Make in India” is symbolised by the lion. With the programme like skill development it is hoped that India will transform its vast army of young population into a productive human resource and a parallel to the IT sector will emerge which can contribute in a huge way to the GDP.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6 |
ID:
193320
|
|
|
|
|
| Summary/Abstract |
Indian Presidency of G-20 is a development as every member gets this opportunity in alphabetical order, expectations have been raised both inside and outside the country about this event. Expectations from India’s Presidency are not entirely misplaced. The realistic understanding of this needs the analysis of three factors: The role and status of G-20 in global affairs; the new opportunities thrown up by India’s present Presidency; and the various challenges India is facing and overcoming to realize these opportunities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7 |
ID:
141062
|
|
|
|
|
| Summary/Abstract |
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies. In so doing, pharmaceutical companies from emerging markets have facilitated the implementation of a key goal of global health policy: widening access to pharmaceutical treatment and prevention. Yet, looking closer at the political economy underlying their involvement, the article exposes a tension between this policy goal and the political economy of pharmaceutical development and production. By declaring access to pharmaceuticals a goal of global health policy, governments and global health partnerships have made themselves dependent on pharmaceutical companies to supply them. Moreover, to provide pharmaceutical treatment and prevention at the global level, they depend on companies to supply medicines and vaccines at extremely low prices. Yet, the development and production of pharmaceuticals is organised around commercial incentives that are at odds with the prices required. The increasing involvement of low-cost suppliers from emerging markets mitigates this tension in the short run. In the long run, this tension endangers the sustainability of global access policies and may even undermine some of the successes already achieved.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8 |
ID:
159646
|
|
|